These patients are particularly vulnerable to infections caused by the disease-causing Aspergillus fungus, a common mold in the environment that easily becomes airborne. Traditionally, infections are diagnosed with X-rays and tests that measure levels of fungal molecules that prompt an immune response in a patient’s blood. Unfortunately, these tests can be inaccurate and can contribute to a misdiagnosis.
To discover a new diagnostic method, the team — led by Allan Brasier, MD, director of UTMB’s Institute for Translational Sciences — studied patients undergoing chemotherapy for leukemia, bone marrow transplants and lung transplants. The researchers discovered a panel of protein biomarkers to help identify the presence of an Aspergillus fungal infection.
The biomarker panel consisted of eight plasma host response proteins, four abundant protein fragments, a fungal cell wall component (β-D-glucan) and a fungal polysaccharide (galactomannan).
“Our data suggest that addition of host response markers may be important additions to detect [Aspergillus fungal infections], and will provide opportunities for earlier interventions and interventional clinical trials,” concluded the study authors.
More articles on diagnostics:
Engineers develop inexpensive, disposable diagnostic device
Misdiagnoses and diagnostic imaging: 2 hospital CEOs on subspecialty radiology’s role
C. diff is over diagnosed by popular molecular tests, study finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.